Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

5.11
-0.1000-1.92%
Volume:224.44K
Turnover:1.14M
Market Cap:159.89M
PE:-1.24
High:5.31
Open:5.17
Low:5.00
Close:5.21
52wk High:50.40
52wk Low:4.54
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.01
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.73
PE(LYR):-1.79

Loading ...

Press Release: Rakovina Therapeutics Announces Results from 2026 Annual General Meeting

Dow Jones
·
Aug 19

Cutia Therapeutics Sets Board Meeting to Approve Interim Results and Consider Dividend

TIPRANKS
·
Aug 19

Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing

TIPRANKS
·
Aug 19

Percheron Therapeutics Files ASX Corporate Governance Statement and Appendix 4G

TIPRANKS
·
Aug 19

Press Release: CARsgen Therapeutics Announces 2026 Interim Results

Dow Jones
·
Aug 19

TScan Therapeutics Faces Loss of Key Amgen Partnership

TIPRANKS
·
Aug 19

Tempest Therapeutics Adjourns Special Stockholder Meeting Again

TIPRANKS
·
Aug 19

CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich

Simply Wall St.
·
Aug 19

Analyst Reaffirms Buy on Rein Therapeutics With Unchanged $4 Target as Phase 2 IPF Trial Advances and Cash Runway Extends to 2028

TIPRANKS
·
Aug 19

Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026

GlobeNewswire
·
Aug 19

Intensity Therapeutics price target raised to $7 from $5 at H.C. Wainwright

TIPRANKS
·
Aug 19

Enliven Therapeutics Initiated at Outperform by William Blair

Dow Jones
·
Aug 18

Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance

TIPRANKS
·
Aug 18

BioMarin to Acquire Alesta Therapeutics, Expanding Skeletal Pipeline

TIPRANKS
·
Aug 18

Obsidian Therapeutics Initiated at Outperform by LifeSci Capital

Dow Jones
·
Aug 18

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

GlobeNewswire
·
Aug 18

BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA

TIPRANKS
·
Aug 18

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

GlobeNewswire
·
Aug 18

Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target

MT Newswires Live
·
Aug 18

Ingenia Therapeutics Goes Public on KOSDAQ

MT Newswires Live
·
Aug 18